ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation
Ligand Pharmaceuticals Incorporated (LGND) M&A Call Transcript [Seeking Alpha]
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
Ligand to Report First Quarter 2026 Financial Results on May 7, 2026
Ligand Pharmaceuticals (LGND) had its price target raised by Citigroup Inc. from $276.00 to $282.00. They now have a "buy" rating on the stock.